W. Sutanto

Localisation of 11β-hydroxysteroid dehydrogenase-tissue specific protector of the mineralocorticoid receptor

In vitro the mineralocorticoid receptor is non-specific and does not distinguish between aldosterone and cortisol. In vivo certain tissues with this receptor are aldosterone selective (eg, kidney and parotid) whereas others with the same receptor are not (eg, hippocampus and heart). Experiments in rats showed that 11 beta-hydroxysteroid dehydrogenase (which converts cortisol to cortisone in man and corticosterone to 11-dehydrocorticosterone in the rat) was much more highly concentrated in aldosterone-selective tissues than in non-selective tissues. The localisation in the selective tissues was such that the enzyme could act as a paracrine or possibly an autocrine mechanism protecting the receptor from exposure to corticosterone. Autoradiographic studies showed that protection is lost when the enzyme is inhibited; 3H-corticosterone and 3H-aldosterone were bound to similar sites. These findings seem to explain why sodium retention, hypokalaemia, and hypertension develop in subjects with congenital deficiency of 11 beta-OHSD and those in whom the enzyme has been inhibited by liquorice.

On the Role of Brain Mineralocorticoid (Type I) and Glucocorticoid (Type II) Receptors in Neuroendocrine Regulation

Administrations of the glucocorticoid receptor antagonist (anti-glucocorticoid, RU38486) and the mineralocorticoid antagonist (anti-mineralocorticoid, RU28318) followed by frequent, sequential blood sampling were employed to investigate the possible role the brain mineralocorticoid receptor (MR, type I) and glucocorticoid receptor (GR, type II) have in the regulation of basal and stress-induced adrenocortical secretion in the rat. The anti-mineralocorticoid and anti-glucocorticoid were administered subcutaneously (s.c.) at doses of 2.5 mg and 1.0 mg/100 g body weight, respectively. Both antagonists were also given intracerebroventricularly (i.c.v.) at a dose of 100 ng/rat. Under basal non-stressed conditions (at the diurnal trough in the morning), injections of either saline, anti-glucocorticoid (s.c. or i.c.v.) or anti-mineralocorticoid (s.c.) did not have effect on the plasma corticosterone level. The anti-mineralocorticoid given intracerebroventricularly, however, caused an elevation of plasma corticosterone up to 60 min after the injection. Exposure of the rats to a novel environment resulted in a large increase in the plasma corticosterone level, which was slightly reduced in the rats treated with the anti-glucocorticoid. In vehicle-treated rats, the level returned to basal values at 90 min, while in the anti-glucocorticoid- and anti-mineralocorticoid-treated groups, it remained elevated for prolonged periods. The present study thus shows that (1) the anti-glucocorticoid RU38486 via the brain GR has no effect on the basal plasma corticosterone level in the morning but interferes with a glucocorticoid negative feedback following stress and (2) the anti-mineralocorticoid RU28318 via the brain MR elevates the basal plasma corticosterone level and enhances adrenocortical secretion following stress.(ABSTRACT TRUNCATED AT 250 WORDS)

Stress, glucocorticoids and development

Publisher Summary This chapter provides an overview of the current understanding of the dynamics of the hypothalamuspituitary-adrenal (HPA) system in the adult rat. The chapter particularly emphasizes on the role of glucocorticoid receptors in this process. In the adult organism, glucocorticoids (GCs) serve a wide variety of regulatory and permissive functions, aimed basically at controlling the organisms responses to stress, and at regulating circadian-driven activities. The principal GC synthesized by the rat adrenal cortex is corticosterone (CORT). CORT levels display a pronounced circadian rhythmicity: they are highest immediately preceding the animals active period, and lowest at the end of this period. During development, however, GCs have also been shown to produce, in experimental animals, permanent effects on growth and differentiation of a number of systems, including the central nervous system. In rats, for example, high doses of GCs administered neonatally cause a decrease in mitosis and myelination, as well as altered neural morphogenesis. In addition, the chapter also reviews some of the relevant human literature and considers the implications of animal studies for the field of human functional teratology.

Ontogeny of type I and type II corticosteroid receptors in the rat hippocampus.

The ontogeny of the corticoid receptors in the rat hippocampus was examined by in vitro [3H]corticosterone (CORT) binding to soluble molecules in the cytosol, using the selective Type II glucocorticoid agonist, RU 28362, to discriminate between Type I and Type II receptor sites. Type I receptors were undetectable until 8 days after birth. From this age on, the receptor showed adult characteristics for both the binding capacity (Bmax) and affinity (Kd). The Type II receptor concentration increased gradually over the observed period; however, at 3 weeks of age concentrations were still only about 65% those found in adults. The binding affinity of Type II to CORT was high during the first week of life but decreased thereafter towards adult value. These data thus suggest clear distinctions in the developmental patterns of Type I and Type II receptors for corticosteroids in the rat.

Corticosteroid receptor types in brain: regulation and putative function

The hypothalamic-pituitary-adrenal (HPA) axis plays an essential role as humoral communication system in adaptive processes. The amine, peptide and steroid components of the axis are apparently needed to maintain homeostasis. Disturbances in homeostasis trigger HPA activity and as the final link in the subsequent cascade of humoral events, function the corticosteriods. In our studies on neuroendocrine aspects of adaptation we have focused on corticosteroid receptors. Here we will summarize biochemical and physiological evidence for the presence of two types of corticosteriod receptors in the brain. These receptors appear to play a key function in the integrative response to stress and participate in regulation of ongoing as well as long-term influences on the adaptive process. Intrinsic to the receptors is their plasticity, which permits the adjustment of receptor number and affinity to changing environmental conditions. Regulation of receptor number appears, however, strikingly different for each receptor type, i.e. homologous vs heterologous regulation. Experiments involving neurotrophic peptides have opened up the route towards understanding this differential regulation. Such peptides not only stimulate adrenocortical hormone secretion, they also seem to modulate steroid receptor number and to facilitate the expression of the steroid receptor.

Central Action of Adrenal Steroids During Stress and Adaptation

Corticosteroids interact with receptors in the central nervous system. These receptors display heterogeneity and can be distinguished as corticosterone- and aldosterone-binding mineralocorticoid receptors and dexamethasone-binding glucocorticoid receptors. Ligand specificity of mineralocorticoid receptors for either corticosterone or aldosterone seems to be determined by co-localized transcortin and the enzyme, 11 beta-hydroxysteroid dehydrogenase. Aldosterone-selective mineralocorticoid receptors appear to be present in the circumventricular organs and the AV3V region of the hypothalamus and mediate behavior that is driven by salt appetite. Highest concentrations of mineralocorticoid receptors are found in neurons of the hippocampus. These limbic mineralocorticoid receptor sites mediate tonic influences of corticosterone on brain processes. Glucocorticoid receptors bind corticosterone with a tenfold lower affinity than do mineralocorticoid receptors, and are widely distributed in neuronal and glial cells of the brain. Glucocorticoid receptors are involved in the termination of the stress response (negative feedback). Studies involving measurement of glucocorticoid receptor mRNA and binding sites have revealed that glucocorticoid receptors are subject to autoregulation. After ADX, glucocorticoid receptor concentration increases, but is reduced after chronic stress, chronic administration of glucocorticoids, and at senescence. A diminished glucocorticoid receptor concentration may compromise the negative feedback action exerted by glucocorticoids after stress. After ADX, mineralocorticoid receptor binding is acutely up-regulated and reaches its maximum between 7 and 24 hours post-ADX. Mineralocorticoid receptor mRNA level shows a transient increase following ADX. Long-term ADX has no effect on the mineralocorticoid receptor concentration, but, interestingly, chronic dexamethasone treatment results in an up-regulation of mineralocorticoid receptors. Mineralocorticoid receptor level is decreased at senescence, but this age-related decrement can be reversed by chronic treatment with the ACTH4-9 analog, ORG 2766. Functionally, mineralocorticoid receptors and glucocorticoid receptors are involved in different aspects of the organization of the stress response, and in conjunction they control the stress responsiveness of the animal.

Long-Lasting Glucocorticoid Suppression of Opioid-Induced Antinociception

The antinociceptive effect of morphine (5 mg/kg body weight i.p.) in rats subjected to various experimental manipulations of the pituitary-adrenocortical system was studied. The absence of adrenal steroids increased the sensitivity to morphine. The following findings suggest that glucocorticosteroids have a long-lasting influence on opioid-induced antinociception, even when the steroids have been removed by adrenalectomy. First, when rats were adrenalectomized in the morning under basal conditions of pituitary-adrenocortical activity (plasma corticosterone level less than 1 microgram %), the subsequent hypersensitivity to morphine-induced antinociception following adrenalectomy either in the morning or in the evening persisted for at least 2 weeks. Second, exposure to a novel environmental (stress of a new cage) or administration of corticosterone (10 mg/kg body weight s.c.) prior to morning adrenalectomy decreased the sensitivity to morphine measured 1 week later. Third, RU 38486, a glucocorticoid antagonist, injected in the lateral cerebral ventricle prior to the evening adrenalectomy increased subsequent morphine antinociception. In attempts to understand the long-term effect on morphine antinociception, the opioid receptor sites were quantified by an in vivo procedure. Quantitative autoradiography of binding sites labeled after intravenous administration of a tracer dose of [3H]-diprenorphine showed a decrease in retention of the labeled opioid in cortical and midbrain regions of rats adrenalectomized in the evening when compared with rats operated in the morning.(ABSTRACT TRUNCATED AT 250 WORDS)

Species-Specific Topography of Corticosteroid Receptor Types in Rat and Hamster Brain

In vivo and in vitro autoradiography with radiolabeled corticosteroid analogs as well as immunocytochemistry with monoclonal antibodies raised against the rat liver glucocorticoid receptor were used to determine the presence and the topography of two corticosteroid receptor systems (type I and type II) in hamster and rat brains. In the rat, the in vivo autoradiograms clearly revealed the retention by the type I receptor of tracer amount of [3H]corticosterone, primarily in the CA1 and CA2 cell field, dentate gyrus and lateral septum. In the hamster, tracer doses of [3H]cortisol were retained not only in the CA1, CA2, dentate gyrus and lateral septum, but also at high level in the CA3 and CA4 areas. In both species, immunocytochemistry showed the widespread distribution of the type II receptor sites in areas such as the hippocampus, lateral septum, hypothalamus (particularly in the paraventricular nucleus), thalamus and cortex (these results were also reflected in the in vitro autoradiography). Strong cell nuclear glucocorticoid immunoreactivity (type II-IR) was observed in the CA1 and CA2 (as well as CA3 and CA4 in the hamster) pyramidal neurons. In the hippocampus of intact animals, type II-IR was seen in the neuronal cell nuclei. Adrenalectomy caused a depletion of the type II-IR signal from the cell nucleus, which returned 1 h following subcutaneous administration of RU 28362 to adrenalectomized animals.(ABSTRACT TRUNCATED AT 250 WORDS)

Ontogeny of mineralocorticoid (type 1) receptors in brain and pituitary: an in vivo autoradiographical study

The ontogeny of high affinity [3H]corticosterone uptake and retention in brain and pituitary of 24-h adrenalectomized rats was examined using autoradiography of in vivo labeled brain sections. Our data indicate: (1) There is specific uptake of radiolabeled steroid in both brain and pituitary already at 2 days of age, following administration of a tracer (2 microCi/g body wt.) dose of [3H]corticosterone. This uptake is maximum around 4-8 days of age and decreases towards adult values around postnatal day 16. (2) High affinity uptake, at least in the brain, probably represents mostly binding to the mineralocorticoid receptor (MR) and not to the glucocorticoid receptor (GR), as it was not displaced by an excess dose of a GR antagonist, RU 38486, and its location in the hippocampus resembled that of MRs in the adult animal. The tracer amounts of [3H]corticosterone circulating after injection in the rat pups resulted in steroid levels comparable to basal levels of non-adrenalectomized animals of equivalent age. Thus, MRs may be the receptors mainly responsible for mediating physiological effects of glucocorticoids during early ontogeny.

ZK91587: a novel synthetic antimineralocorticoid displays high affinity for corticosterone (type I) receptors in the rat hippocampus

In vitro cytosol binding assays have shown the properties of binding of a novel steroid, ZK91587 (15 beta, 16 beta-methylene-mexrenone) in the brain of rats. Scatchard and Woolf analyses of the binding data reveal the binding of [3H] ZK91587 to the total hippocampal corticosteroid receptor sites with high affinity (Kd 1.9 nM), and low capacity (Bmax 17.3 fmol/mg protein). When 100-fold excess RU28362 was included simultaneously with [3H] ZK91587, the labelled steroid binds with the same affinity (Kd 1.8 nM) and capacity (Bmax 15.5 fmol/mg protein). Relative binding affinities (RBA) of various steroids for the Type I or Type II corticosteroid receptor in these animals are: Type I: ZK91587 = corticosterone (B) greater than cortisol (F); Type II: B greater than F much greater than ZK91587. In the binding kinetic study, ZK91587 has a high association rate of binding in the rat (20.0 x 10(7) M-1 min-1). The steroid dissociates following a one slope pattern (t 1/2 30 h), indicating, the present data demonstrate that in the rat hippocampus, ZK91587 binds specifically to the Type I (corticosterone-preferring/mineralocorticoid-like) receptor.